These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 33098047)
41. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma. Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940 [TBL] [Abstract][Full Text] [Related]
42. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Rini BI; Tomita Y; Melichar B; Ueda T; Grünwald V; Fishman MN; Uemura H; Oya M; Bair AH; Andrews GI; Rosbrook B; Jonasch E Clin Genitourin Cancer; 2016 Dec; 14(6):499-503. PubMed ID: 27236772 [TBL] [Abstract][Full Text] [Related]
43. Axitinib for the treatment of advanced renal cell carcinoma. Akaza H; Fukuyama T Expert Opin Pharmacother; 2014 Feb; 15(2):283-97. PubMed ID: 24328549 [TBL] [Abstract][Full Text] [Related]
45. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology. Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816 [TBL] [Abstract][Full Text] [Related]
46. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. Spisarová M; Melichar B; Vitásková D; Študentová H Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119 [TBL] [Abstract][Full Text] [Related]
47. Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Eto M; Uemura H; Tomita Y; Kanayama H; Shinohara N; Kamei Y; Fujii Y; Umeyama Y; Ozono S; Naito S; Akaza H; Cancer Sci; 2014 Dec; 105(12):1576-83. PubMed ID: 25283266 [TBL] [Abstract][Full Text] [Related]
48. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Hutson TE; Al-Shukri S; Stus VP; Lipatov ON; Shparyk Y; Bair AH; Rosbrook B; Andrews GI; Vogelzang NJ Clin Genitourin Cancer; 2017 Feb; 15(1):72-76. PubMed ID: 27498023 [TBL] [Abstract][Full Text] [Related]
49. A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. Kollmannsberger C; Choueiri TK; Heng DYC; George S; Jie F; Croitoru R; Poondru S; Thompson JA Oncologist; 2021 Mar; 26(3):182-e361. PubMed ID: 33289953 [TBL] [Abstract][Full Text] [Related]
50. Axitinib in metastatic renal cell carcinoma: beyond the second-line setting. Umeyama Y; Shibasaki Y; Akaza H Future Oncol; 2017 Sep; 13(21):1839-1852. PubMed ID: 28707479 [TBL] [Abstract][Full Text] [Related]
51. Real-world pharmacokinetics and pharmacodynamics of everolimus in metastatic breast cancer. Fukudo M; Ishibashi K; Kitada M Invest New Drugs; 2021 Dec; 39(6):1707-1715. PubMed ID: 34041638 [TBL] [Abstract][Full Text] [Related]
53. Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study. Huang J; Shi G; Wang Y; Wang P; Zhang J; Kong W; Huang Y; Wang S; Xue W Future Oncol; 2022 Apr; 18(12):1461-1471. PubMed ID: 35103528 [TBL] [Abstract][Full Text] [Related]
54. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan. Miyake H; Harada KI; Ozono S; Fujisawa M Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522 [TBL] [Abstract][Full Text] [Related]
55. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612 [TBL] [Abstract][Full Text] [Related]
56. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057 [TBL] [Abstract][Full Text] [Related]
57. Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. Chen Y; Rini BI; Motzer RJ; Dutcher JP; Rixe O; Wilding G; Stadler WM; Tarazi J; Garrett M; Pithavala YK Target Oncol; 2016 Apr; 11(2):229-34. PubMed ID: 26400730 [TBL] [Abstract][Full Text] [Related]
58. Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma. Yang Y; Huang H; Li T; Gao Q; Song Y; Wang Z Front Immunol; 2021; 12():728750. PubMed ID: 34764951 [TBL] [Abstract][Full Text] [Related]
59. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Rixe O; Bukowski RM; Michaelson MD; Wilding G; Hudes GR; Bolte O; Motzer RJ; Bycott P; Liau KF; Freddo J; Trask PC; Kim S; Rini BI Lancet Oncol; 2007 Nov; 8(11):975-84. PubMed ID: 17959415 [TBL] [Abstract][Full Text] [Related]
60. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]